Dalfampridine (Ampyra) coverage for multiple sclerosis-related walking impairment
Defines medical necessity, prior authorization and documentation expectations, dosing limits, and coverage durations for dalfampridine (Ampyra) across Commercial, HIM/ICHRA, and Medicaid lines of business for members with multiple sclerosis who have walking impairment.
No material clinical or coverage changes in this revision.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.